Recbio(HKEX:02179) is an innovative vaccine company founded in 2012. With the vision of "Become the Leader of Innovative Vaccine in the Future," Recbio takes "Protect Human Health with Best-in-Class Vaccines" as its mission. It has established three major cutting-edge technology platforms including novel adjuvants platform, protein engineering platform, and immunological evaluation platform. Recbio has a high-value vaccine portfolio consisted of recombinant protein, HPV vaccine candidates, COVID-19 vaccine candidates, shingles vaccine candidates, influenza vaccine candidates, adults TB vaccine candidates, etc. The core scientific team has more than 20 years of experience in the development and commercialization of innovative vaccines. For more information, please visit https://www.recbio.cn/.
Company Details
- Employees
- 20
- Founded
- 2012
- Address
- Taizhou, Jiangsu, Cn
- Industry
- Biotechnology
- Website
- https://www.recbio.cn/
- Keywords
- Vaccine, Adjuvant, HPV Vaccine, COVID19 Vaccine.
- HQ
- Taizhou, Jiangsu
Recbio Questions
Recbio's website is https://www.recbio.cn/
Recbio's LinkedIn profile is https://cn.linkedin.com/company/recbio
Recbio has
20 employees.
View email and phone details for 20
employees at Recbio.
Recbio's industry is
Biotechnology
Recbio's top competitors are
Visen Pharmaceuticals,
Inxmed 应世生物,
Antengene,
Duality Biologics,
Innolake Biopharm,
Recbio.cl,
Rayzebio,
Tg Therapeutics, Inc.,
Asieris Pharmaceuticals,
Eluminex Biosciences Limited.
Recbio's categories are Biotechnology
Recbio's founding year is 2012
